Virtual Reality Exposure Therapy in Agoraphobic Participants
NCT ID: NCT00734370
Last Updated: 2018-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
55 participants
INTERVENTIONAL
2008-10-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. enhanced VRET making use of the latest avatar technology with
2. exposure in vivo in agoraphobic participants
3. wait-list control.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Virtual Reality Exposure Therapy Versus Exposure in Vivo for Social Phobia
NCT01746667
Single Session Virtual Reality Therapy in Acrophobia - and the Role of Respiration
NCT03893214
A Protocol for a Virtual Reality Exposure Therapy for Fear of Flying.
NCT05939986
Virtual Reality Exposure Versus In Vivo Exposure for Fear of Heights
NCT04737915
Virtual Reality Exposure Therapy for Speech Anxiety Using Commercial Hardware and Software
NCT03001154
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VRET
Virtual Reality Exposure Therapy for agoraphobic participants
Virtual Reality Exposure Therapy for agoraphobic participants
This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of
* Psycho-education, breathing training and cognitive restructuring
* Virtual reality Exposure to agoraphobic situations and interoceptive exposure
* Relapse prevention
Exposure in vivo
Standard exposure in vivo for panic disorder
Standard exposure in vivo for agoraphobic participants
This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of
* Psycho-education, breathing training and cognitive restructuring
* Standard exposure in vivo to agoraphobic situations and interoceptive exposure
* Relapse prevention (according to the protocol of Craske \& Barlow)
Wait-list control
Wait-list control group. Participants from this arm are randomized to the two active conditions after 10 weeks of waiting.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Virtual Reality Exposure Therapy for agoraphobic participants
This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of
* Psycho-education, breathing training and cognitive restructuring
* Virtual reality Exposure to agoraphobic situations and interoceptive exposure
* Relapse prevention
Standard exposure in vivo for agoraphobic participants
This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of
* Psycho-education, breathing training and cognitive restructuring
* Standard exposure in vivo to agoraphobic situations and interoceptive exposure
* Relapse prevention (according to the protocol of Craske \& Barlow)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between the ages of 18-65 years
* Sufficient fluency in Dutch to complete treatment and research protocol
Exclusion Criteria
* Current use of Beta-blockers
* Current use of tranquilizers (Benzodiazepines)
* Unstable psychotropic medication
* Substance dependence
* Psychosis
* Depression with suicidal ideation
* Posttraumatic Stress Disorder
* Dementia or other severe cognitive impairment
* Bipolar Disorder
* Borderline Personality Disorder
* Anti-social Personality Disorder
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VU University of Amsterdam
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paul M.G.Emmelkamp
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul MG Emmelkamp, Professor
Role: PRINCIPAL_INVESTIGATOR
University of Amsterdam
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Amsterdam
Amsterdam, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KP-2008-518
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.